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ABSTRACT 
 
The process of sexual differentiation is central for reproduction of almost all metazoan, and  
therefore for maintenance of  practically all multicellular organisms.   In sex development we 
can distinguish two different processes¸ sex determination , that is the developmental 
decision that directs the undifferentiated embryo into a sexually dimorphic individual. In 
mammals, sex determination equals gonadal development. The second process known as sex 
differentiation takes place once the sex determination decision has been made through factors 
produced by the gonads that determine the development of the phenotypic sex. Most of the 
knowledge on the factors involved in sexual development came from animal models and 
from studies of cases in whom the genetic or the gonadal sex does not match the phenotypical 
sex, i.e. patients affected by disorders of sex development (DSD). 
Generally speaking, factors influencing sex determination are transcriptional regulators, 
whereas factors important for sex differentiation are secreted hormones and their receptors. 
This review focuses on these factors and whenever possible, references on the “prismatic” 
clinical cases are given. 
 
Keywords: Sex development; sex determination, sex differentiation; Ovary; Testis;  Disorders 
of sex development (DSD); Bipotential state. 
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Abbreviations:  
 
DSD: Disorders of sex development 
Pax2: Paired Homeobox 2 
Emx2: Empty spiracle homolog 2 
Lhx9: Lim Homeobox protein 9 
WT1: Wilms Tumor 1  
GATA4: GATA-binding protein 4 
SRY: Sex determining Region Y 
SOX9: SRY- box 9 
SF1/NR5A1: Steroidogenic Factor 1/Nuclear Receptor subfamily 5, group A, member 1 
DAX1: Dosage sensitive sex reversal, Adrenal hypoplasia congenital critical region on the X 
chromosome gene 1 
DMRT1: Doublesex and MAB3-Related Transcription factor 1 
DHH: Desert Hedgehog 
ATRX: Alpha Thalassemia, mental Retardation syndrome, X-linked 
CBX2: Chromobox homolog 2 
TSPYL1: Testis-specific protein Y-like-1 
MAMLD1: Mastermind-Like Domain-Containing Protein 1 
PGD2S: Prostaglandin D2 synthase 
RSPO1: Root-plate specific Spondin 1 
WNT4/FST: Wingless Type MMTV intergration site family, member 4/Follicostatin 
FOXL2: Forkhead transcription factor 
AMH/AMHR = MIS: Anti-Müllerian Hormone/ Receptor = Müllerian Inhibiting Substance 
HOXA: Homeobox A 
Lim1/LHX1: Lim Homeobox protein 1 
LH/CG: Luteinizing Hormone/Corionic Gonadotropin 
POF: Premature ovarian failure 
ODG: Ovarian dysgenesis 
FMR1: Fragile X Mental Retardation 1   
DIAPH2: Diaphanous  (dia) homolog 2 
GDF9: Growth Differentiation Factor 9 
BMP15: Bone Morphogenic Protein 15   
NOBOX:  Newborn Ovary Homeobox  
FIGLA:  Factor in Germ Line Alpha  
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1. PHYSIOLOGY OF SEX DEVELOPMENT.   
In sex development we can distinguish two different processes¸  sex determination that is the 
developmental decision that directs the undifferentiated embryo into a sexually dimorphic 
individual and sex differentiation that takes place once the sex determination decision has 
been made through factors produced by the gonads that determine the development of the 
phenotypic sex.  At the beginning of gestation (1st and 2nd  week) embryos of the two sexes 
differ only for their karyotypes. Starting at week 3 specific genes lead to the differentiation of 
the gonads, which in turn produce hormones inducing anatomical and psychological 
differences, leading to behavioral differences that are ultimately influenced by the social 
environment. As very nicely put by  Sekido and Lovell-Badge  : “Overall, sex determination 
is a story of opposing forces and crucial alliances but, although the winning team takes all, its 
rule can be surprisingly tenuous“ 1 
The main steps of intrauterine sex differentiation are depicted in Fig. 1.  At gestational weeks 
6-7 the paramesonephric duct (Müllerian duct) develops next to the mesonephric duct.  If 
testes develop and secrete testosterone, the mesonephric (Wolffian) duct increases in size and 
differentiate into epididymis, vas deferens, and prostate. A glycoprotein secreted from the 
testicular Sertoli cells known as Anti-Müllerian Hormone (AMH) or Müllerian Inhibiting 
Substance (MIS), results in Müllerian duct regression. If testes do not develop, the 
mesonephric duct does not grow and eventually degenerates, whereas the paramesonephric 
duct proliferates and the fallopian tube, uterus, and upper third of the vagina develop (Fig.2). 
In mammals, including humans, the differentiation of the gonads is the turning point of this 
whole process. The classical text-book theory says that in the presence of the sex determining 
region on the Y-chromosome (SRY), the default ovarian pathway of sex determination will 
be inhibited and therefore testes will be formed. In the XX individual due to the absence of 
SRY no inhibition of the default program will take place and ovaries will develop. Ovarian 
determining factors might help the process of differentiation. However, these factors are yet 
to be determined. The second  model called the Z-factor theory  was proposed to explain the 
cases where XX individuals develop testes in the absence of SRY. According to this theory, 
the XX gonad expresses a factor that has both anti-testis and pro-ovary function. SRY in XY 
individuals  acts as an  inhibitor of the Z-factor to lift the block on the male pathway. In this 
case, the bipontential gonad will differentiate into a testis 2. The Z-factor remains unknown. 
It is important to notice that most of the knowledge on the factors involved in sexual 
development came from studies of cases in whom the genetic or the gonadal sex does not 
match the phenotypical sex, i.e. patients affected by defects of sex development 3 and from 
animal models. This review focuses on these factors and whenever possible, references on the 
“prismatic” clinical cases are given . 
Figure 3 and table 1 summarize the role of such factors and the effects of their mutations in 
mice and men. 
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2. FACTORS INVOLVED IN SEX DETERMINATION 
 
2.1. INDIFFERENTIATED STATE (BIPOTENTIAL) 
 
 
Pax2 
 
Pax-2 is a transcriptional regulator of the paired-box family and is widely expressed during 
the development of both ductal and mesenchymal components of the urogenital system. Pax-
2 homozygous mutant newborn mice lack kidneys, ureters and genital tracts.  These defects 
might be attributed to dysgenesis of both ductal and mesenchymal components of the 
developing urogenital system 4.  
 
In humans, genetic defects in PAX2 are identified in renal-coloboma syndrome, without 
genito-urinary abnormalities. 
 
Emx2 
 
The homeobox gene Emx2 is a mouse homologue of a Drosophila head gap gene empty 
spiracles (ems) and is essential for the development of dorsal telencephalon 5. At the same 
time, Emx2 is expressed in the epithelial components of the developing urogenital system 
and, in Emx2 mutant mice, the kidneys, ureters, gonads and genital tracts were completely 
missing. Degeneration of the Wolffian duct and mesonephric tubules was also abnormally 
accelerated in these mice without the formation of the Mullerian duct 6.   
 
Mutations in EMX2 are a rare cause schizencephaly and somatic mutations in EMX2 have 
been found in endometrial carcinomas 7, but, again, no human sex developement defect due 
to EMX2 mutations has been described to date.  
 
Lhx9 
Transcripts of the LIM homeobox gene Lhx9 are present in urogenital ridges of mice at 
embryonic day 9.5; later they localize to the interstitial region as morphological 
differentiation occurs. In mice lacking Lhx9 function, germ cells migrate normally, but 
somatic cells of the genital ridge fail to proliferate and a discrete gonad fails to form. In the 
absence of testosterone and anti-Mullerian hormone, genetically male mice are 
phenotypically female. The expression of steroidogenic factor 1 (Sf1), a nuclear receptor 
essential for gonadogenesis, is reduced to minimal levels in the Lhx9-deficient genital ridge, 
indicating that Lhx9 may lie upstream of Sf1 in a developmental cascade. Lhx9 mutants do 
not exhibit additional major developmental defects 8.  
 
Although  LHX9 mutations may underlie certain forms of isolated gonadal agenesis in 
humans, none of such mutations has yet been found. 
WT1 
The WT1 gene encodes a zinc finger DNA-binding protein that is inactivated in some Wilms’ 
tumors. Mutation analysis in human patients and genetic experiments in mice revealed that 
WT1 has a role in development besides in tumor suppression. WT1 has at least 4 splicing 
variants depending on the presence of exon 5 (+/- 17 amino acids in the mature protein) 
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and/or 9 nucleotides coding for the 3 amino acids KTS (+/-KTS). Post-trancriptional 
modifications of  the Wt1 pre-mRNA lead to the production of up to 24 isoforms, which 
increase the complexity of Wt1 action.  WT1 is already expressed within the undifferentiated 
gonad, and its importance there has been demonstrated in Wt1-/- mice, in which the gonads 
undergo apoptosis. Since the gonads and adrenal cortex share a common primordium 9 it is 
not a surprise that adrenal glands are also affected in these mice 10.  Expression of Sf1 and 
expression of WT1 in the gonad begin about simultaneously  and might be dependent. 
Wilhelm and Englert  demonstrated that WT1, and more specifically its DNA binding form 
WT1(-KTS), can activate the Sf1 promoter in vitro and in vivo 11. The apoptotic phenotype in 
Wt1-knockout mice might therefore be caused by a lack of Sf1 expression. Alternatively, 
WT1 might activate an Sf1-independent pathway required for adrenogenital survival. This 
could include the anti-apoptotic factor Bcl-2, which might be directly activated by WT1  12. A 
second role for WT1 during gonad formation occurs at the level of sex determination, through 
its control over Sry expression.  Other potential targets during gonad formation include Wnt-4 
13, Dax1 14  and AMH, all of which seem to be activated by WT1(-KTS) variants. Dax1, a 
gene that can interfere with male sexual development in mouse and man was proposed to be a 
repressor of the AMH promoter that could displace WT1 from its complex with Sf1.  For 
more details see 15 
Mutations in the WT1 gene have been identified in patients with renal disease , such as 
Wilms tumor and isolated diffuse mesangial sclerosis (IDMS), and complex diseases like 
WAGR syndrome, Frasier syndrome, Denys-Drash syndrome (DDS), and Meacham 
syndrome. The association of aniridia, hemihypertrophy, and other congenital anomalies with 
Wilms tumor was first described by Miller et al in 1964 16. The syndrome subsequently 
became known as the WAGR syndrome (Wilms tumor, Aniridia, Genitourinary anomalies, 
and mental Retardation syndrome). Aniridia is due to the PAX6 gene, whereas the other 
features are due to WT1 gene defects 17. Frasier syndrome is a rare disorder defined by 46, 
XY DSD and progressive glomerulopathy 18. Patients present with normal female external 
genitalia, streak gonads, and XY karyotype, and frequently develop gonadoblastoma. Wilms 
tumor is not a feature of the syndrome. Frasier syndrome is caused by a mutation in the donor 
splice site in intron 9 of WT1, with the predicted loss of the +KTS isoform 19. In contrast 
with Frasier syndrome, most individuals with Denys-Drash syndrome 20 21 have ambiguous 
genitalia or a female phenotype, an XY karyotype, and dysgenetic gonads. Renal symptoms 
are characterized by diffuse mesangial sclerosis, usually before the age of 1 year, and the 
patients frequently develop Wilms tumor. Pelletier identified mutations of various types in 
WT1 as the molecular cause of DDS 22. Meacham described two 46, XY individuals with a 
novel constellation of genital, cardiac, and pulmonary malformations. The genital 
abnormalities consisted of a true double vagina, retention of mullerian structures, and 
undervirilization of the external genitalia 23. Although  phenotype and sometimes phenotype 
overlap with that of DDS patients 24, the Meacham syndrome patients do not have renal 
disease. 
 
GATA4 
GATA-4, a member of the GATA family of transcription factors is required for proper 
development of the heart.  It is also present in the gonads and may be a regulator of gonadal 
gene expression. In mice of both sexes, GATA-4 specifically marked the developing somatic 
cell lineages (Sertoli in testis and granulosa in ovary) but not primordial germ cells. 
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Interestingly, abundant GATA-4 expression was maintained in Sertoli cells throughout 
embryonic development but was markedly down-regulated shortly after the histological 
differentiation of the ovary on embryonic day 13.5. This pattern of expression suggested that 
GATA-4 might be involved in early gonadal development and possibly sexual dimorphism 25  
In humans, mutations in GATA4 have been related to atrial septal heart defects only. 
 
2.2. TESTES 
SRY 
The discovery of Sry, the mammalian Y-chromosomal sex-determining gene, promised to 
answer many questions relating to the genetics and developmental biology of sex 
determination 26 27. The simple transgenesis experiment of adding Sry function to an XX 
mouse to induce male phenotype confirmed the master switch role of this gene 28. But since 
then, little else about this gene has proven to be simple or straightforward. The fact that Sry 
resides on the Y chromosome makes it vulnerable to degradation. As a result, it is minimally 
conserved and shows some functional flaws, surprising indeed for a gene on which survival 
and propagation of mammalian species so much depends. 
In the mouse embryo, Sry exhibits a tightly-controlled and limited spatiotemporal profile of 
expression in the precursors of Sertoli cells of the XY gonad 29-31. Early studies revealed that 
Sry is first expressed around 10.5 days post coitum (dpc), shortly after the emergence of the 
genital ridges, reaches peak levels of expression at 11.5 dpc, and is extinguished shortly after 
12.5 dpc in mouse 32-34. SRY clearly throws a molecular switch to engage a male-specific 
cascade of molecular events, but continued expression of SRY is not required for these events 
to unfold. 
Despite almost 20 years of work since the discovery of SRY, little is known about its 
biochemical function. The HMG domain, a DNA-binding and DNA-bending motif, plays a 
central role, being the only region conserved between species and the site of almost all 
clinical mutations causing XY gonadal dysgenesis. It seems that SRY acts on a single gene, 
Sox9, the expression of which is then rapidly reinforced by positive regulatory loops. SOX9 
then drives Sertoli cell formation and, therefore, testis differentiation. If SRY is absent or 
fails to act in time, Sox9 is silenced and development of the follicle cell and ovary ensues, 
with β-catenin being one of the crucial components driving this process.  
 
Mutations in SRY are the cause of 46,XY DSD due to pure gonadal dysgenesis, originally 
described as XY, female with gonadal dysgenesis 35. 
 
SOX9 
Several lines of evidence indicate that Sox9 is the best candidate for a direct SRY target gene 
30 31 36. First, Sox9 expression is strongly upregulated soon after the expression of SRY 
begins, whereas it is downregulated in the ovary. Second, cell-fate mapping experiments 
show that SRY-positive cells exclusively become SOX9-positive Sertoli cells. Third, 
heterozygous mutations in SOX9 are responsible for the human skeletal malformation 
syndrome, campomelic dysplasia  in which most XY patients have male to female sex 
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reversal. Similarly, targeted Sox9 ablation in mice also leads to ovary development in XY 
embryos 37 38 
However, the expression of Sox9 in the genital ridge is not entirely dependent on SRY and 
the normal gonadal Sox9 transcriptional regulation consists of  a SRY-independent initiation 
a  SRY-dependent upregulation; and SRY-independent maintenance in adult life . 
SF1 is a good candidate for initiating or sensitizing Sox9 expression because early sex-
independent expression of Sox9 is abolished in Sf1 null mutant gonads 30 39.  
SF1 sensitizes Sox9, initiating a low level of expression in the genital ridge of both sexes at 
10.5 dpc. In the male, SF1 (probably with other factors such as WT1−KTS) also activates Sry 
expression. Sox9 expression is upregulated by the action of SRY together with SF1, whereas 
it is downregulated in the female. This downregulation is unlikely to be passive, implying the 
presence of one or more currently unknown repressors. After the transient expression of Sry 
has ceased, high levels of SOX9 are maintained by its direct autoregulation and via FGF9 
signaling (Fig. 4). 
As mentioned, mutations in SOX9 lead to 46,XY DSD and skeletal abnormalities known as 
camptomelic dysplasia. 
 
SF1/NR5A1 
Human SF-1/NR5A1 is a 461 amino acid protein that shares structural homology with other 
members of the nuclear receptor superfamily (www.nursa.org). Critical functional domains of 
this protein include: an amino-terminal 2 zinc finger DNA-binding domain (DBD), an 
accessory DNA-binding region, a hinge region, and a ligand-binding domain (LBD) that 
forms an AF-2 structure.  
The expression pattern of SF-1 is consistent with its central role in regulating adrenal 
development, gonad determination and differentiation, and in the hypothalamic-pituitary 
control of reproduction and metabolism. 
In the mouse, Sf-1 is expressed in the early adrenogonadal primordium from 9 dpc and, 
thereafter, in the developing adrenal gland and gonad 40-42. In humans, SF-1 expression has 
been shown in the developing adrenal gland and bipotential gonad at 32-33 days post 
conception 43 44. Following testis determination (from around 42 days onwards in humans), 
SF-1 expression is consistently maintained in the somatic cells of the early testis, where it 
may play a crucial role together with SRY in supporting SOX9 expression 36. In Sertoli cells, 
SF-1 activates expression of AMH from around 7 weeks gestation, which leads to the 
regression of Müllerian structures in the developing male fetus. In Leydig cells, SF-1 
activates the expression of steroidogenic enzyme systems from 8 weeks gestation, which 
results in androgenization of the external genitalia. In females, persistent expression of SF-1 
has been reported in early ovarian development in humans 44, whereas Sf-1 expression may 
decline in the mouse. However, SF-1 is detectable in somatic cells (granulosa and theca cells) 
of the adult ovary 45. The exact role SF-1 plays in the ovary is unclear, as the related nuclear 
receptor LRH-1 (NR5A2) may also have a role in regulating aromatization and oestrogen 
synthesis. 
In addition to its expression in the adrenal gland and gonad, SF-1 is also expressed in the 
developing ventromedial hypothalamus (VMH), pituitary gonadotropes, and spleen 46-48.  
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Deletion of the gene (Nr5a1) encoding Sf-1 in XY mice results in impaired adrenal 
development, complete testicular dysgenesis with Müllerian structures, and female external 
genitalia. 
 
These studies in mice prompted the search for the human counterpart. Initial studies to 
identify SF1/NR5A1 mutations in humans focused on patients with primary adrenal failure, 
46,XY gonadal dysgenesis and Müllerian structures. The first prismatic case was identified 
by Achermann et al in 1999 in a patient with such phenotype 49.  
Mutation in the human SF1/NR5A1 gene  has a phenotypic spectrum that  ranges from 
complete testicular dysgenesis with Müllerian structures, through individuals with mild 
clitoromegaly or genital ambiguity, to severe penoscrotal hypospadias or even anorchia 50. 
Although not essential for ovarian determination 51,  heterozygote mutations in NR5A1 have 
recently been linked to ovarian insufficiency 52. 
DAX1/NR0B1 
DAX1 encodes a member of the orphan nuclear hormone receptor (NHR) family of 
transcriptional regulators. The C-terminal domain shows homology to the ligand-binding 
domain (LBD) of related NHRs, although a ligand remains unknown. The N-terminal domain 
represents a novel domain comprising 3.5 repeats of a 65–67-amino acid motif containing 
two putative zinc fingers, and possibly defining a nucleic acid-binding domain. 
DAX1 has a  transcriptional silencing domain which has been proposed to interact directly 
with corepressors to mediate repression 53. At least two corepressors, Alien and NCoR, 
interact in vitro with the DAX1 C-terminus 54 55, one of which (Alien) is expressed in the 
testis 56. 
In cultured cells, DAX1 represses Sf1-mediated transcriptional activation of steroidogenic 
genes, such as Cyp11A, Cyp17 and Cyp19 essential for the synthesis of androgens and 
estrogens, it interacts with the AF2 domain of ligand-bound estrogen receptors, ERα and ERβ 
and repress ER-mediated activation of target reporter genes. It is probable that DAX1 and 
SF1 interact during gonadogenesis in a similar manner to that seen during steroidogenesis.. 
Together, these studies suggest a common function for DAX1 as a repressor of SF1 trans-
activation in both steroidal and gonadal tissues.  
 
Inactivating mutations in DAX1 (NR0B1) can lead to adrenal insufficiency with 
glucocorticoid and mineralocorticoid deficiency 57. These mutations are responsible for 
many, but not all, patients with the cytomegalic form of adrenal hypoplasia congenita (AHC). 
These mutations also cause hypogonadotropic hypogonadism (HH) which is consistent with 
the expression of DAX1 in the hypothalamus and pituitary.  
Duplications of the region of the X chromosome containing DAX1 cause dosage sensitive sex 
reversal  57 58. Transgenic XY mice with additional copies of the mouse DAX1 ortholog 
expressed at high levels do not have male to female sex reversal, but do show delayed 
testicular development 59.  
DMRT1 
Raymond and co-workers 60 isolated the male sexual regulatory gene mab3 61 from the 
nematode Caenorhabditis elegans and found that it is related to the Drosophila melanogaster 
sexual regulatory gene 'doublesex' (dsx) 62. Both genes encode proteins with a DNA-binding 
motif that Raymond et al. referred to as the 'DM domain.' The same authors identified a 
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human gene, which they designated DMT1, that encodes a protein with a DM domain and 
found that DMT1 is expressed only in testis.  
Muroya et al. 63 reported clinical and molecular findings in five 46, XY  and one 46, XX 
patients with distal 9p monosomy. Some of the XY and the XX subjects had female external 
genitalia, one case showed ambiguous external genitalia, and another exhibited male external 
genitalia with left cryptorchidism and right intrascrotal testis. Gonadal explorations at 
gonadectomy revealed the presence of various morphologies, from streak gonad and right 
agonadism, to hypoplastic testes.  
 
DHH 
In an animal model Bitgood and collaborators 64 found that male Desert Hedgehog (Dhh)-null 
mice were sterile and failed to produce mature spermatozoa, and that the peripheral nerves of 
Dhh-null mutant mice were highly abnormal. The perineurial sheaths surrounding the nerve 
fascicles were abnormally thin, and extensive minifascicles consisting of perineurial-like 
cells were formed within the endoneurium. 
 In a patient with 46,XY partial gonadal dysgenesis (PGD) associated with minifascicular 
polyneuropathy, Umehara et al. 65 found a homozygous missense mutation at the initiating 
codon in exon 1 of the DHH gene , which predicted a failure of translation. 
 
ATRX 
The protein encoded by this gene contains an ATPase/helicase domain, and thus it belongs to 
the SWI/SNF family of chromatin remodeling proteins. 
XY patients with deletions or mutations in the ATRX gene display varying degrees of sex 
reversal, implicating ATRX in the development of the human testis 66. To explore further the 
role of ATRX in mammalian sex differentiation, Pask et al. 67 cloned and characterized the 
homologous gene in a marsupial. To their surprise, active homologs of ATRX were detected 
on the marsupial Y as well as the X chromosome. The Y-borne copy (ATRY) displayed 
testis-specific expression. This, as well as the sex reversal of ATRX patients, suggested that 
ATRY is involved in testis development in marsupials and may represent an ancestral testis-
determining mechanism that predated the evolution of SRY as the primary mammalian male 
sex-determining gene. The authors found no evidence for a Y-borne ATRX homolog in 
mouse or human, implying that this gene has been lost in eutherians and its role supplanted 
by the evolution of SRY from SOX3 as the dominant determiner of male differentiation.  
The range of genital phenotypes caused by ATRX mutations together with the observation 
that ATRX patients always have some testicular tissue, suggest that ATRX functions in sex 
differentiation rather than sex determination in humans 68. 
CBX2/M33 
When Katoh-Fukui and coworkers ablated the M33 gene in mice, they observed sex reversal 
in XY animals 69. M33 is a member of the Polycomb(PcG)/Trithorax (TrxG) proteins.  
Polycomb group (PcG) proteins are highly conserved regulatory factors that were initially 
discovered in Drosophila. PcG genes are best known for their role in maintaining silent 
expression states of Hox genes during development, while trithorax group (trxG) proteins 
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maintain. They act by regulating chromatin structure and chromosome architecture at their 
target loci (for more informations 
http://www.igh.cnrs.fr/equip/cavalli/link.PolycombTeaching.html). 
M33 deficient mice have male-to-female sex reversal with perfectly normal female gonads 
and genitalia in 50% of the cases, but are invariably sterile.  Similarly, we made the 
intriguing discovery of a loss-of-function double heterozygote mutation state in a 46,XY girl 
with normal ovaries at histology, normal uterus and external female genitalia, accidentally 
diagnosed because of a discrepancy between prenatal karyotype and phenotype at birth. 
Functional studies demonstrated that the mutated CBX2 does not properly bind to and does 
not adequately regulate the expression of target genes essential for sex development such as 
SF1/NR5A1. Our data identify CBX2 as essential for normal human  male gonadal 
development , suggest that it lies upstream of SRY in the human sex development cascade 
and  identify a novel autosomal recessive cause of defect of sex development 70.  
TSPYL1 
Testis-specific protein Y-like-1 is a member of the TSPY-SET-NAP1L1 family of chromatin 
modifiers 71 that are involved in nucleosome assembly 72. Besides being linked to beta globin 
regulation 73, mutations in TSPYL1 were found by Puffenberger e co-workers in a previously 
unrecognized syndrome called  Sudden Infant Death with Dysgenesis of the Testes (SIDDT). 
Genotypic males with SIDDT had fetal testicular dysgenesis and ambiguous genitalia, with 
findings such as intraabdominal dysplastic testes, deficient fetal testosterone production, 
fusion and rugation of the gonadal sac, and partial development of the penile shaft. 46,XX 
sexual development was normal. Affected infants appeared normal at birth, but developed 
signs of visceroautonomic dysfunction early in life followed by death before age 12 months 
of abrupt cardiorespiratory distress 74 75. Interestingly, cases of sudden infant death without 
testicualr dysgenesis do not have mutations in TSPYL1 75, suggesting the testis-specific role 
of this protein. 
MAMLD1/CXorf6 
In the course of identifying the gene responsible for X-linked myotubular myopathy 
(MTM1), which maps to proximal Xq28, Laporte et al. (1997) identified a novel gene, 
Mastermind-Like Domain-Containing Protein 1 (MAMLD1, also called Chromosome X 
Open Reading Frame 6 :CXORF6, F18) 76, expressed in several tissues including fetal Sertoli 
and Leydig cells around the critical period for sex development (E12.5-E14.5) . Most patients 
with deletion of this region of chromosome X also had ambiguous genitalia. The proof of the 
importance of MAMLD1 came when Fukami et al performed direct sequencing of the coding 
exons 3-6 of the CXORF6 gene and their flanking splice sites in 166 individuals with various 
types of 46,XY disorders of sex development. They identified 3 nonsense mutations in 4 
Japanese individuals with penoscrotal hypospadias as the most evident phenotype 77. Two 
years later, again Fukumi et al  demonstrated  that MAMLD1 acts as a transcritpion factor by 
transactivating the promoter if a non canonical Notch target gene hairy/enhancer of split 3 
(Hes3), auguments testosterone production, most likely under the regulation of SF1.78   
More recently, a gain-of-function mutation in MAMDL1  was described in a 46,XX DSD 
woman with virilization (clitoromegaly, streak gonads, small uterus) 79, suggesting a role of 
this protein in ovarian development. 
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PGD2S 
Lipocalin-type prostaglandin D2 synthase (L-PGDS) and hematopoietic prostaglandin D2 
synthase (H-PGDS) are two enzymes expressed in the testes and involved in the nuclear 
translocation and expression of SOX9, a central factor in testis determination during foetal 
life. Knockout of L- and H-PGDS in male mice induces delayed testicular organisation and a 
uni- or bilateral testis migration defect. 
 
Wilhelm et al found that Pgds was expressed in embryonic mouse Sertoli cells immediately 
after the onset of Sry and Sox9 expression. Pgds upregulation was mediated by Sox9, but not 
Sry, and required the binding of dimeric Sox9 to a paired SOX recognition site within the 
Pgds 5-prime flanking region 80. 
The process of testicular descent is not fully understood, but several factors, such as Hoxa-10, 
epidermal growth factor (EGF) and calcitonin gene-related peptide (CGRP), together with 
androgens and insulin-like hormone 3 (Insl3), have been suggested to regulate it. Philibert et 
al an H-PGDS gene (but not L-PGDS)  abnormality was identified in one boy referred to our 
pediatric endocrinology clinic at 15 months with bilateral cryptorchidism and severe growth 
retardation (-4DS). Functional analysis of the mutations showed about a 40% decrease in 
glutathione transferase activity (indispensable for PGDS activity) and total prostaglandin D2 
synthase abolition. Taken together, these data suggested that H-PGDS defect can be 
responsible for cryptorchidism in human 81. 
 
 
2.3. OVARIES 
RSPO1 
Kamata et al 82 identified the mouse R-spondin gene, which encodes a 265-amino acid 
sequence with a calculated molecular mass of 29 kD. Unlike other secretory proteins of the 
thrombospondin family, R-spondin contains no apparent secretion cleavage site, but has a 
putative N-terminal nuclear localization signal. R-spondin transcripts were observed mainly 
in central nervous system (CNS) tissues. Outside the CNS, R-spondin transcripts were 
detected in forelimb buds after 10 dpc, especially in the body trunk and the proximal 
posterior part of the anterior limb bud. Kim and co-workers found that human R-spondin is 
expressed in enteroendocrine cells as well as in epithelial cells from various tissues 83.  
In mice, the ovarian phenotype  of  XX, Rspo1-/- is striklingly similar to that of Wnt4 -/- 
female mice, especially for the formation of coelomic vessels and the presence of functional 
steroidogenic cells. These animal models suggest that the ovarian phenotype in Rspo1-/- mice 
is at least in part due to failing overexpression of Wnt4 in XX gonads. In contrast Rspo1 -/- 
female mice do not show adrenal or uterine abnormalities, as Wnt4 -/- mice do, in agreement 
to the fact that Rspo1 is not expressed in adrenals or mesonephros, indicating that activation 
of Wnt4 in these organs is independent of Rspo1 (For review see 84 ). 
The essential role of R-spondin 1  in human ovarian development was demonstrated by 
studyind  individuals with palmoplantar hyperkeratosis with squamous cell carcinoma of skin 
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and 46 XX, DSD in whom Parma et al. demonstrated mutations in the RSPO1 gene 85. The 
authors concluded that RSPO1 is produced and secreted by fibroblasts and regulates 
keratinocyte proliferation and differentiation. The presence of 'functional' testes in the sex-
reversed individuals was confirmed by the absence of mullerian derivatives and by the 
masculinization of the internal and external genitalia, presumably induced by functioning 
Sertoli and Leydig cells, respectively. All sex-reversed individuals were sterile. Notably, the 
data suggested that normal RSPO1 is not required for testis differentiation and function. 
Parma et al speculated that RSPO1 may synergize with WNT4 in XX gonads to stabilize 
beta-catenin  85. 
 
WNT4 
WNT4 is a member of the WNT family of secreted molecules that function in a paracrine 
manner to affect a number of developmental changes. WNT proteins bind to members of the 
Frizzled (FZ) family of cell-surface receptors and possibly to the single-pass transmembrane 
protein LDL-receptor-related proteins 5 and 6 (LRP5 and LRP6) 86. The binding of WNT to 
FZ ultimately leads to reduced degradation of -catenin with consequent β-catenin-
dependent activation of T-cell factor/lymphocyte enhancer factor transcription factors, and 
induction of Wnt-responsive genes  87. Wnt proteins can also signal via  a β -catenin 
independent non-canonical pathway involving protein kinase C (PKC) and c-jun NH2-
terminal kinase (JNK) 88.  
(Readers interested in learning more about WNT proteins should visit the informative site  
http://www.stanford.edu/~rnusse/wntwindow.html).  
Wnt4 is produced in ovarian somatic cells (pre-granulosa cells). Wnt4 up-regulates Dax189, a 
gene known to antagonize SF1, and thereby inhibits steroidogenic enzymes. Vainio and 
collaborators 90 observed in Wnt4-deficient mice that gonadal development and steroidogenic 
function were affected exclusively in female Wnt4-knockout mice, whereas both male and 
female mice had similar defects in kidney development and adrenal function. Wnt4-knockout 
female mice were masculinized, as demonstrated by the absence of Müllerian ducts and the 
presence of Wolffian ducts, and expressed the steroidogenic enzymes 3β-hydroxysteroid 
dehydrogenase and 17α-hydroxylase, which are required for the production of testosterone 
and are normally suppressed in the developing female ovary. The ovaries of these mice also 
had less oocytes, suggesting a role of Wnt4 in the life of female germ cells. This function is 
crucial for the organization of ovarian structure, since female germ cells have a central role in 
this process and in  maintenance of  the ovary, as demonstrated by the fact that when oocytes 
are either absent 91 or lost after follicle formation 92 ovarian follicles never form or degenerate 
subsequently. In contrast, testis development proceeds in the absence of germ cells.  WNT4 
and follicostatin 93  appear  to maintain oocyte viability once germ cells have reached their 
final destination in the gonad.  
 
In humans, more copies of WNT4, due to  duplication of chromosome 1p31-p35, were found 
in a patient with ambiguous genitalia, severe hypospadia, fibrous gonads and remnants of 
both Müllerian and Wolffian ducts 89, i.e. male-to-female sex reversal.  On the other end of 
the spectrum, when both copies of the gene are inactive, as in the case of homozygote 
mutations, a severe clinical entity,  called the SERKAL syndrome  results 94.  The syndrome 
was described in three 46,XX fetuses and is  characterized by female-to-male sex reversal 
with ambiguous genitalia,  gonadal morphology ranging from ovotestis to normal testis, renal 
agenesis, adrenal hypoplasia, pulmonar and cardiac abnormalities. 
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In the middle of such spectrum one might expect to find patients with intermediate defects of 
sex development. Searches for clinically relevant WNT4 mutations sometimes in  large 
cohorts of these patients were unsuccessful 95. We described three women with absent 
Müllerian structures (uterine and fallopian tubes) and clinical signs of androgen excess. Their 
phenotype resembles that of patients with the Mayer–Rokitansky–Küster–Hauser syndrome 
and is also strikingly similar to that of Wnt4-knockout female mice. This constellation of 
findings prompted us to search  for and allowed us to find mutations in the WNT4 gene in 
these patients 96-99. 
 
From a more clinical point of view,  we agree with Clement-Ziza 100 that the WNT4 mutation 
should not be looked for in MRKH syndrome. However, MRKH-like syndrome associated 
with hyperandrogenism should be investigated for mutations in this gene, and may classify 
for a distinct clinical entity. 
 
FOXL2 
FOXL2 is a single-exon gene encoding a forkhead/winged helix (fkh) transcription factor 101. 
FOXL2 is a nuclear protein. In vertebrates, FOXL2 is one of the earliest known markers of 
ovarian differentiation 102. Thus, it may play a role in the early stage of development of the 
ovarian somatic compartment. As it is still strongly expressed in postnatal and adult follicular 
cells, it may also play a role in follicle development and/or maintenance during fertile life. 
Despite the importance of FOXL2 in ovarian development and maintenance, only a few 
transcriptional targets have been described so far 103 104 In the context of the pituitary, FOXL2 
seems to stimulate the expression of the gonadotropin-releasing hormone (GnRH) receptor. 
Foxl2 influence the expression of aGSU, StAR and several steroidogenic enzymes.  
Mutations in FOXL2 are responsible for blepharophimosis–ptosis–epicanthus inversus 
syndrome (BPES), which is a genetic disease leading to complex eyelid malformation and 
other mild craniofacial abnormalities and can be associated with premature ovarian failure 101 
105 
 
Genes and proteins responsible for  maintanance of ovarian function, such as BMP15, GDF9 
and NOBOX, whose mutations cause premature ovarian insufficiency, will be discussed later 
in this chapter. 
 
2.4. MÜLLERIAN DUCTS 
 
AMH 
 
Anti-Mullerian hormone (AMH) produced by fetal Sertoli cells is responsible for regression 
of Mullerian ducts, the anlage for uterus and Fallopian tubes, during male sex differentiation. 
A member of the transforming growth factor-beta superfamily, AMH signals through two 
transmembrane receptors, type II which is specific and type I receptors, shared with the bone 
morphogenetic protein family.  
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Mutations of the AMH and AMH receptor type II (AMHR-II) genes lead to persistence of the 
uterus and Fallopian tubes in males 106-109 
 
HOXA 
 
HOX genes are a family of regulatory molecules that encode conserved transcription factors 
controlling aspects of morphogenesis and cell differentiation during normal embryonic 
development. HOXA Hox genes are also expressed in the adult uterus. Hox genes are 
essential both for the development of müllerian tract in the embryonic period and adult 
function. Sex steroids regulate Hox gene expression during embryonic and endometrial 
development in the menstrual cycle. EMX2 and β3-integrin acting downstream of Hoxa10 
gene are likely involved in both these developmental processes 110 111 
 
The role of WNT4 and EMX2 in sex development has been discussed above .  
 
 
Lim1/LHX1 
 
Lim1 encodes a LIM-class homeodomain transcription factor that is essential for head and 
kidney development. In the developing urogenital system, Lim1 expression has been 
documented in the Wolffian (mesonephric) duct, the mesonephros, metanephros and fetal 
gonads. Using, a Lim1 lacZ knock-in allele in mice, we identified a previously unreported 
urogenital tissue for Lim1 expression, the epithelium of the developing Müllerian duct that 
gives rise to the oviduct, uterus and upper region of the vagina of the female reproductive 
tract. Lim1 expression in the Müllerian duct is dynamic, corresponding to its formation and 
differentiation in females and regression in males. Although female Lim1-null neonates had 
ovaries they lacked a uterus and oviducts. A novel female mouse chimera assay was 
developed and revealed that Lim1 is required cell autonomously for Müllerian duct 
epithelium formation. These studies demonstrate an essential role for Lim1 in female 
reproductive tract development 112. 
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3. GONADAL DYSGENESIS 
Gonadal dysgenesis is characterized by a progressive loss of primordial germ cells on the 
developing gonads of an embryo. This loss leads to extremely hypoplastic and dysfunctioning 
gonads mainly composed of fibrous tissue, hence the name streak gonads. 
Although most etiologies of gonadal dysgenesis have been already described in  previous 
sections of this chapter, some causes merit a special mention.  
A. Chromosomal abnormalities 
1. Turner syndrome,  pure gonadal dysgenesis.  45,X0, variants and mosaics  
The syndrome is named after Henry Turner, an Oklahoma endocrinologist, who described it 
in 1938 113. It is a chromosomal disorder in which all or part of one of the X chromosome is 
absent. In some cases, the missing chromosome is present in some cells but not others, a 
condition referred to as mosaicism.  There are characteristic physical abnormalities, such as 
short stature, swelling, broad chest, low hairline, low-set ears, and webbed necks. Girls with 
Turner syndrome typically experience gonadal dysgenesis , which results in amenorrhea  and 
sterility. Concurrent health concerns are also frequently present, including congenital heart 
disease, hypothyroidism , diabetes, vision problems, hearing concerns, and many other 
autoimmune diseases. Finally, a specific pattern of cognitive deficits is often observed, with 
particular difficulties in visuospatial, mathematical, and memory areas. A detailed review of 
such a complex disease is beyond the purpose of this chapter and can be read for instance in 
114.  
2. Klinefelter syndrome, seminiferous tubules dysgenesis.  47, XXY, variants and 
mosaics  
The syndrome was named after Harry Klinefelter, an endocrinologist at Massachusetts 
General Hospital in Boston, Massachusetts, who first described it in 1942 115. The principal 
effects are development of small testicles and reduced fertility . Some degree of language 
learning impairment may be present,  and neuropsychological testing often reveals deficits in 
executive functions.  In adults, possible characteristics vary widely and include little to no 
signs of affectedness, a lanky, youthful build and facial appearance, or a rounded body type 
with some degree of gynecomastia. Some variations e.g. (XXYY) and mosaicism are possible 
with different severity of symptoms. For more details see 116 117  118.  
 
3. Mixed gonadal dysgenesis and ovostesticular DSD (true hermaphroditism).  
Mixed gonadal dysgenesis: some authors reserve the term mixed gonadal dysgenesis (MGD) 
for individuals who present a 45,X/46,XY karyotype with a testis on one side and a streak on 
the other side ( 119 and references therein); other authors apply the term to all patients who 
have varying degrees of asymmetrical gonadal dysgenesis with testicular differentiation on 
either side, bilateral streak testis, or bilateral dysgenetic testis .  Ovotesticular DSD (OT-DSD 
or true hermaphroditism) is the rarest form of intersexuality in humans, and the term is 
 
17
applied to an individual who has both well-developed ovarian and testicular tissues. The 
differentiation of OT-DSD from MGD is important for three reasons. First, a bilateral 
gonadectomy is recommended as soon as possible in all individuals with MGD containing Y-
chromosome material. There is no benefit in delaying surgery because approximately one 
third of patients with MGD develop gonadoblastoma during the 1st to 4th decades of life and 
because 30% of gonadoblastomas are overgrown by more malignant germ cell tumors, such 
as germinoma, endodermal sinus tumor, immature teratoma, embryonal carcinoma, or 
choriocarcinoma . In OT-DSD, however, only the removal of the opposite gonad from the 
assigned gender and a biopsy of remaining gonadal tissue for histological evaluation may be 
appropriate. Second, gender assignment is critical for the treatment of patients of  OT-DSD 
because these patients usually do not have any other developmental malformations, and thus 
normal sexual and reproductive functions can be achieved by proper management and sex 
assignment at a young age . After the removal of the testicular portion of an ovotestis, about 
38% of these patients with a 46,XX karyotype menstruate by age 14 years 120; ovulation 121 
and successful childbearing have also been described  122 123. In contrast, it is important that 
bilateral gonadectomies be performed in patients with MGD before the patient reaches 
puberty, not only to prevent the development of malignant tumors but also to avoid 
virilization if the patient is to be raised as female. Third, certain medical problems, such as 
deficient immunoglobulin levels, aberrant bony development of inner ear structures, and 
cardiovascular and renal anomalies, are more common in MGD patients than in OT-DSD 
patients; therefore, patients with MGD should receive more medical attention. 
For a differential diagnosis, chromosomal constitutions are not helpful. Various types of 
chromosomal abnormalities have been described in cases of OT-DSD, such as 46,XX; 
46,XY; 46,XX/46,XY; 45X/46,XY; and others. MGD cases also have heterogeneous 
chromosomal changes but are usually characterized by a 45,X/46,XY; 45,X/47,XYY; or 
46,XY karyotype 124 . The pathogenesis of OT-DSD and MGD still remains unclear. In cases 
of 46,XX true hermaphroditism, mosaicism with a Y-bearing cell line at low level 125 or 
partial inactivation of the Y-bearing X chromosome that was formed during paternal meiosis  
126 127 have been suggested to explain the mechanism of abnormal sexual development. In 
cases of MGD, mutations in SRY genes were usually absent 128; however the cytogenetic 
mosaicism, mutation in the genes downstream of SRY, and unpaired or incompletely paired 
X chromosome have been proposed as a mechanism to cause defective formation of the 
follicular mantle and degeneration of oocytes. 
Histopathologically, there are no major differences in the testicular part of the gonads 
between the two entities. On the other hand a rise of testosterone levels after hCG is observed 
exclusively in cases of OT-DSD and will not occur in MGD patients.  The presence of 
numerous primordial follicles containing primary oocytes with or without maturing follicles 
is considered well-developed ovarian tissue when making a definitive diagnosis of  OT-DSD 
after birth. 
For more extensive review see 119.  
B. Single gene defects 
B.1. 46, XX  
Besides Section 2.3. and Table 1, an additional  form of gonadal dysgenesis in women is 
Premature Ovarian Failure (POF), defined as menopause at age less than 40 years.  
POF1 is associated to  premutations (mutations that do not cause symptoms and needs a 
second mutation to become „full“) in  Fragile X Mental Retardation 1 (FMR1) gene (Xq26-
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q28) 129. In an international collaborative study of 760 women from fragile X families, 
130found that 395 carried a premutation,  128 carried a full mutation, and 237 were 
noncarriers. In 63 (16%) of the premutation carriers, menopause occurred before the age of 
40, compared with none of the full-mutation carriers and 1 (0.4%) of the controls, indicating 
a significant association between premature menopause and premutation carrier status. 
POF2A is caused by mutations in the Drosophila  Diaphanous  (dia) homolog 2 (DIAPH2, 
Xq22). In the fruit fly mutant alleles of dia affect spermatogenesis or oogenesis and lead to 
sterility. Bione et al 131 identified DIAPH2, which they called DIA, as the gene disrupted by a 
breakpoint in a family with premature ovarian failure and stated that DIAPH2 is the first 
human member of the FH1/FH2 protein family. Members of this family affect cytokinesis 
and other actin-mediated morphogenetic processes that are required in early steps of 
development. 
POF2B. Bione et al 131considered the POF1B gene (Xq21) a candidate for premature ovarian 
failure because it is located within the critical region for normal ovarian function, escapes X 
inactivation, and a breakpoint in the third intron was identified in a POF patient with an X;1 
translocation 132 but they could not demonstrate any mutation in POF1B in their POF 
patients.   In the same work they determined that Pof1B expression is absent from adult 
mouse ovary but is present between embryonic day 16.5 and postnatal day 5, suggesting that 
the gene may be critical for the steps required for early ovary development leading to the 
final number of germ cells. Based on its expression pattern in mouse development Bione et al   
also hypothesized that POF1B could play a role in the pairing of meiotic chromosomes and 
that alteration in its function could lead to cell death and a drastic reduction in the final 
number of oocytes created during ovarian development. Alternatively, POF1B may act as an 
antiapoptosis factor, to slow down the process of germ cell loss; as a consequence, loss of 
function of POF1B could lead to exaggerated germ cell apoptosis and POF. In 2006 Lacombe 
et al. 133 identified a G-to-A transition at nucleotide 1132 in exon 10 of the POF1B gene that 
resulted in an arg329-to-gln (R329Q) mutation in a Lebanese family in which premature 
ovarian failure mapped to the Xq21.1-q21.33. Affected family members were homozygous. 
The R329Q variant altered the arginine within an amino acid triplet, serine-leucine-arginine, 
that is part of a protein kinase C phosphorylation recognition site. 
POF3 is caused by mutations in FOXL2 (see above) 
POF4 is associated with defects of Bone Morphogenic Protein 15  (BMP15; Xp11.2). This 
entity is also known as Ovarian Dysgenesis 2 (ODG2). The bone morphogenetic protein 
(BMP) family is part of the transforming growth factor-beta superfamily, which includes 
large families of growth and differentiation factors. By Northern blot analysis, Dube et al 134 
showed that mouse Bmp15 is expressed only in the ovary and precisely  in the oocyte soon 
after primordial follicles are recruited, and that expression is maintained until after ovulation. 
Studies by Aaltonen and coworkers 135 showed that in human ovary BMP15 (which they 
called GDF9B) is  expressed in the oocytes of late primary follicle. Otsuka et al 136 showed 
BMP15 expression in oocytes throughout follicular development. The importance of BMP15 
for human disease was firstly  proven by Di Pasquale et al 137  who  reported an Italian family 
in which 2 sisters had hypergonadotropic ovarian failure due to ovarian dysgenesis and a 
dominant negative mutation in BMP15. Later reports confirmed the role of BMP15 in POF 
138 139. 
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POF5.  Newborn Ovary Homeobox (7q35) NOBOX is a homeobox gene that is 
preferentially expressed in oocytes. In mice, it is essential for folliculogenesis and regulation 
of oocyte-specific genes 140. In a 35-year-old Caucasian woman with premature ovarian 
failure Qin et al 141 identified heterozygosity for a 1064G-A transition in exon 6 of the 
NOBOX gene, resulting in an arg355-to-his (R355H) substitution within the highly 
conserved homeodomain region. 
POF6.   Factor in Germ Line Alpha (FIGLA, 2p12) is a helix-loop-helix transcription factor 
expressed in all ovarian follicular stages and in mature oocytes, with less frequent expression 
in preimplantation embryos. Zhao and co-workers 142 analyzed the FIGLA gene in 100 
Chinese women with premature ovarian failure and identified a 22-bp deletion and a 3-bp in-
frame deletion in 2 patients, respectively, that were not found in controls. 
POF7 is related to mutations in SF1/NR5A1 (see above). 
Ovarian DysGenesis (ODG1).  Hypergonadotropic ovarian dysgenesis with normal 
karyotype can be caused by mutations in the gene encoding follicle-stimulating hormone 
receptor (FSHR, 2p21-p26).  Elliott et al  143 reported the condition in 3 sisters who had 
normal stature and sex chromatin but had never menstruated and had severe osteoporosis. 
Somatic features of Turner syndrome were not found. In the Finnish population in which 
ovarian dysgenesis with normal XX karyotype is relatively common (approximately 1 in 
8,300 females), Aittomaki et al  144 demonstrated that affected females are homozygous for a 
C-to-T transition in exon 7 of the FSHR gene, predicting an ala189-to-val substitution in the 
extracellular ligand-binding domain of the protein.  
FSHR mutations also appear to play a role in  Ovarian Hyperstimulation Syndrome. Greb and 
collaborators 145  showed that the FSH receptor ser680/ser680 genotype was associated with 
higher ovarian threshold to FSH, decreased negative feedback of luteal secretion to the 
pituitary during the intercycle transition, and longer menstrual cycles.  
Syndrome-associated ODG:  
Perrault syndrome is characterized by ovarian dysgenesis and sensorineural deafness 146 147. 
Although the exact genetic cause of the disease remains unknown, there is evidence for an 
autosomal recessive mode of inheritance 147. 
Immunodeficiency, pulmonary fibrosis, ODG. Somech et al 148described 2 sisters, born of 
first-cousin parents of Sri Lankan descent, who presented in infancy with immunodeficiency, 
gonadal dysgenesis, and fatal pulmonary fibrosis. The infants displayed no dysmorphic 
features. Immune studies demonstrated combined humoral and cellular abnormalities 
including reduced immunoglobulin production, absence of lymphoid tissue, markedly 
reduced T lymphocyte numbers and function, and reduced newly thymus-derived T cells. 
Both infants succumbed to rapidly progressive pulmonary fibrosis; autopsy revealed streak 
ovaries bearing no discernible oocytes. The molecular basis of the disease is not known. 
Mitochondrial dysfunction. Two sisters were described by  Hisama et al 149 with 
hypergonadotropic hypogonadism, marked short stature, and recurrent episodes of 
dehydration with metabolic acidosis. Both patients had normal intelligence and normal 
46,XX karyotypes. Laboratory studies suggested mitochondrial dysfunction; however, results 
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of mitochondrial DNA studies and of biochemical analysis of electron transport chain activity 
in skeletal muscle were normal. 
 
B.2. 46, XY  
Besides Section 2.2. and Table 1 Testes,  an entity called alopecia universalis, XY gonadal 
dysgenesis with ambiguous genitalia with an XY karyotype and SRY positivity and 
laryngomalacia was described. El-Shanti et al. 150 reported 5 individuals from 2 unrelated 
families from Jordan with alopecia universalis congenita, gonadal dysgenesis, and 
laryngomalacia that persisted beyond infancy. An additional feature of this entity was growth 
delay due to growth hormone deficiency.  
C. Environmental 
Testicular dysgenesis syndrome. The term testicular dysgenesis syndrome (TDS) was first 
coined in 2001 151. It was hypothesized that many cases of abnormal spermatogenesis, 
cryptorchidism, hypospadias, and testicular cancer may have a common aetiology, and that 
all these clinical problems may result from an irreversible developmental disorder originating 
in early fetal life. Etiological factors that explain how TDS may arise  include genetic defects 
(mosaicisms for sex chromosome aneuploidy) and polymorphism (still unclear), 
environmental and lifestyle factors, and intrauterine growth disorders, which may act 
separately or in concert. Exposure to endocrine-disrupting compounds such as phthalates 
(mainly used as plasticizers), which act as anti-androgens, seem to be a central risk factors. 
Lifestyle such as maternal smoking during pregnancy 152  and increasing body mass index in 
young men also negatively influence testicular function 153. These factors lead to testicular 
dysgenesis with decreased Leydig cell and Sertoli cells function. Leydig cell deficiency 
causes androgen insufficiency and INSL3 decrease explaining cryptorchidism,  hypospadia 
and impaired spermatogenesis. Sertoli cells dysfuntion contributes to the infertility and to the 
onset of testicular cancer (for review see 154 ). Chapter 7 discusses this problem in greater 
details.  
 
4. FACTORS INVOLVED IN SEX DIFFERENTIATION. 
 
LH/CG RECEPTOR, STEROIDOGENIC ENZYMES, STEROID RECEPTORS 
 
The role of these factors in sex development will be discussed in great detail in Chapters 4-6
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FIGURE LEGENDS 
Figure 1: Embryonic development. GW: Gestational Week. Data derived from PC Sizonenko 
in Pediatric Endocrinology, edited by J. Bertrand, R. Rappaport, and PC Sizonenko, 
(Baltimore: Williams & Wilkins, 1993), pp. 88-99. 
Figure 2: The undifferentiated sexual system at 6-7 week of gestation. Precursor structure 
and their mature counterparts have the same color. Fossum G. Atlas of Clinical Gynecology: 
Pediatric and Adolescent Gynecology. Edited by Morton Stenchever (series editor), Alvin F. 
Goldfarb. 
Figure 3 : Sexual Development cascade.  Mutations in various genes can lead to a variety of 
syndromes of dysgenesis involving the müllerian or wolffian ducts, gonads, kidneys, and 
adrenal glands as a result of a deficiency or excess of the proteins shown. For abbreviations 
see title page.  Modified from McLaughlin and Donahoe, 2004. 155. 
Figure 4: A time-line of events in mammalian sex determination (simplified). After the 
establishment of the bipotential genital ridge by  several genes, the early expression of Sf1 
and Wt1 initiates also that of Sox9 in both sexes. β-catenin also begin to accumulate as a 
response to Rspo1–Wnt4. In XX cells, β-catenin levels accumulate to repress SOX9 activity. 
In XY cells, with the contribuition of CBX2, increasing levels of SF1 activate Sry expression 
and then SRY, together with SF1, increase Sox9 expression. CBX2 influences directly SF1 
expression and might do so indirectly by removing the DAX1 repression on SF1. Once SOX9 
levels reach a critical threshold, several positive regulatory loops are initiated, including 
autoregulation of its own expression and formation of feed-forward loops via FGF9 or PGD2 
signaling. If SRY activity is weak, low or late, it fails to boost Sox9 expression before β-
catenin levels accumulate sufficiently to shut it down. At later stages,  in XX gonads, FOXL2 
increases and can maintain granulosa (follicle) cell differentiation by repressing Sox9 
expression. In the testis, SOX9 promotes the testis pathway, including Amh activation, and it 
also probably represses ovarian genes, including Wnt4 and Foxl2. Solid lines : validated  
influence; broken line: possible influence. 
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